A Case of Giant Cell Tumor of the Fibula
DOI:
https://doi.org/10.20344/amp.21067Keywords:
Denosumab/therapeutic use, Fibula, Giant Cell Tumor of Bone/drug therapy, Giant Cell Tumor of Bone/pathologyAbstract
N/a.
Downloads
References
WHO Classification of Tumours Editorial Board. WHO classification of soft tissue and bone tumours 5th. Lyon: IARC Publications; 2020.
van Langevelde K, McCarthy CL. Radiological findings of denosumab treatment for giant cell tumours of bone. Skeletal Radiol. 2020;49:1345-58. DOI: https://doi.org/10.1007/s00256-020-03449-1
Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019;139:1339-49. DOI: https://doi.org/10.1007/s00402-019-03167-x
Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18:4415-24. DOI: https://doi.org/10.1158/1078-0432.CCR-12-0578
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.